Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors.

Abstract excerpt

The clinical efficacy and durability of KRASG12C-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRASG12C-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy
• Share to Mutation
• Share to Neoplasms